Clarification of guidance on the use of tacrolimus and pimecrolimus for atopic eczema
History
A list of downloadable documents created during development.
Other information
Background information
-
-
TA82 Atopic dermatitis (eczema) - pimecrolimus and tacrolimus: appendix A - static list review decision - July 2015
-
-
TA82 Atopic dermatitis (eczema) - pimecrolimus and tacrolimus: HTA report
-
TA82 Atopic dermatitis (eczema) - pimecrolimus and tacrolimus: HTA report (PDF 1.64 MB)
-
-
-
Review proposal for TA82: provisional consultees and commentators
-
Review proposal for TA82: provisional consultees and commentators (PDF 58 KB)
-
TA82 Atopic dermatitis (eczema) - pimecrolimus and tacrolimus: comments table
-
TA82 Atopic dermatitis (eczema) - pimecrolimus and tacrolimus: comments table (PDF 40 KB)
-
-
Comments table - April 2009
-
-
-
Final Appraisal Determination
-
Final Appraisal Determination: Tacrolimus and pimecrolimus for atopic eczema information
-
Final Appraisal Determination
-
-
Additional analysis on the assessment report - prepared by PenTAG
-
Additional analysis on the assessment report - prepared by PenTAG (PDF 197 KB)
Appraisal Consultation Document
TA82 Atopic dermatitis (eczema) - pimecrolimus and tacrolimus: HTA report
-
TA82 Atopic dermatitis (eczema) - pimecrolimus and tacrolimus: HTA report
-
TA82 Atopic dermatitis (eczema) - pimecrolimus and tacrolimus: HTA report (PDF 1.64 MB)
Protocol for the appraisal of pimecrolimus and tacrolimus for atopic eczema
-
Protocol for the appraisal of pimecrolimus and tacrolimus for atopic eczema
-
Protocol for the appraisal of pimecrolimus and tacrolimus for atopic eczema (PDF 167 KB)